The Latest Breaking News from PFE

The healthcare sector is set for significant growth due to advancements in pharma technology, increasing demand for personalized medicines, and resilience even in economic downturns. Therefore, investors might consider buying quality pharmaceutical stocks like Pfizer (PFE), Johnson & Johnson (JNJ), and AbbVie (ABBV) for defensive investing. Read on.

Volatility is back on Wall Street, which is bound to scare some investors. Meanwhile, Pfizer and Starbucks are two high dividend names with limited downside which conservative investors can consider now.

Pfizer has underperformed relative to the broader market over the past year, yet Wall Street analysts remain moderately bullish about the stock’s outlook.

Pfizer reported a notable year-over-year decline in Q2 earnings, but the results still beat expectations. Here's what investors should know.

Pfizer's stock shows signs of a potential rebound, buoyed by recent pipeline successes in hemophilia and obesity treatments, an attractive 5% dividend yield, and a rock-bottom valuation. This makes it an appealing dividend stock for value and income investors as the drug giant prepares to report earnings.

As Pfizer gears up to release its second-quarter earnings this month, analysts project a double-digit bottom-line dip.

Pfizer's stock presents a compelling investment opportunity, trading at an attractive valuation with a high dividend yield, as the company makes promising progress on its oral obesity drug, danuglipron, in a market dominated by injectable treatments.

Marine Le Pen’s RN and Hungary’s Fidesz have joined forces. But Europe’s far right is fractured and Orbán isolated, says political scientist Cas Mudde

Amid market volatility, three value stocks - American International Group (AIG), Pfizer (PFE), and Schlumberger (SLB) - emerge as potential long-term investments for passive income, offering attractive valuations, solid dividends, and growth prospects for investors.

These dividend stocks have consistently paid dividends with yields over 6%.

Pfizer has recently lagged the Nasdaq Composite, but analysts are optimistic about the stock’s prospects.